全球首创!信达生物公布 PD-1/IL-2α-bias 双抗融合蛋白三项最新临床数据

Insight数据库
May 28, 2025

2025 年 ASCO 大会上,信达生物公布了首创新型 PD-1/IL-2α-bias双特异性抗体融合蛋白 IBI363 三项最新临床数据,针对黑色素瘤、结直肠癌和非小细胞肺癌,均成功入选口头报告。标题:首创新型 PD-1/IL-2α-bias双特异性抗体融合蛋白 IBI363 在免疫治疗后的晚期肢端及黏膜黑色素瘤患者中的疗效与安全性摘要号:2502会议类型:口头报告登记号:NCT05460767...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10